Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin’s lymphoma

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Expert Opinion on Emerging Drugs

• Publication date

  2018-04-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14728214.2018.1479396PMID 29781323
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials

  2018cited by this paper
• Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial

  2017cited by this paper
• Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.

  2017cited by this paper
• PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors

  2017cited by this paper
• Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.

  2017cited by this paper
• CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL.

  2017cited by this paper
• Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model

  2017cited by this paper
• Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)

  2017cited by this paper
• Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.

  2017cited by this paper
• Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL.

  2017cited by this paper
• BGB-3111, a Highly Specific BTK Inhibitor, Is Well Tolerated and Highly Active in Chinese Patients with Relapsed/Refractory B-Cell Malignancies: Initial Report of a Phase 1 Trial in China

  2017cited by this paper
• Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

  2017cited by this paper
• Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.

  2017cited by this paper
• Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib.

  2017cited by this paper
• First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

  2016cited by this paper
• Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.

  2016cited by this paper
• Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma

  2016cited by this paper
• Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

  2016cited by this paper
• Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.

  2016cited by this paper
• Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside

  2016cited by this paper
• Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.

  2016cited by this paper
• The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

  2016cited by this paper
• A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

  2016cited by this paper
• Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-δ,γ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab

  2016cited by this paper
• Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.

  2016cited by this paper
• Results of a Phase 2 Trial Evaluating Efficacy and Safety of Entospletinib (GS-9973) in Patients with Mantle Cell Lymphoma

  2016cited by this paper
• CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma

  2016cited by this paper
• Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma

  2016cited by this paper
• Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

  2015cited by this paper
• Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.

  2015cited by this paper
• An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.

  2015cited by this paper
• Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

  2015cited by this paper
• Management of adverse events associated with idelalisib treatment: expert panel opinion

  2015cited by this paper
• Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

  2015cited by this paper
• FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma

  2015cited by this paper
• The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

  2015cited by this paper
• Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.

  2015cited by this paper
• A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia

  2015cited by this paper
• Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM).

  2015influential reference
• Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.

  2015cited by this paper
• Ibrutinib in previously treated Waldenström's macroglobulinemia.

  2015cited by this paper
• Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

  2015cited by this paper
• Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202

  2014cited by this paper
• Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial

  2014cited by this paper
• PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

  2014influential reference
• Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

  2014cited by this paper
• A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor

  2014cited by this paper
• A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).

  2014influential reference
• Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

  2014cited by this paper
• Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.

  2014cited by this paper
• Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.

  2014cited by this paper
• Ibrutinib resistance in chronic lymphocytic leukemia.

  2014cited by this paper
• a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL

  2014cited by this paper
• Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

  2014cited by this paper
• Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

  2013cited by this paper
• Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

  2013cited by this paper
• PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.

  2013cited by this paper
• The World Health Organization Classification of Lymphoid Neoplasms

  2013cited by this paper
• BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

  2013cited by this paper
• P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.

  2013cited by this paper
• Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

  2013cited by this paper
• Targeting pathological B cell receptor signalling in lymphoid malignancies

  2013cited by this paper
• Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

  2013cited by this paper
• Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

  2013cited by this paper
• Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

  2013cited by this paper
• Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.

  2013cited by this paper
• Treatment of older patients with mantle-cell lymphoma.

  2012cited by this paper
• Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.

  2012cited by this paper
• MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

  2012cited by this paper
• Self-antigen recognition by follicular lymphoma B-cell receptors.

  2012cited by this paper
• CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.

  2011cited by this paper
• Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.

  2011cited by this paper
• Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities.

  2011influential reference
• Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

  2010cited by this paper
• The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

  2010cited by this paper
• Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

  2010cited by this paper
• Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

  2010cited by this paper
• Phosphoinositide 3-Kinase p110δ Regulates Natural Antibody Production, Marginal Zone and B-1 B Cell Function, and Autoantibody Responses1

  2009cited by this paper
• Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

  2008cited by this paper
• SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.

  2008cited by this paper
• Deletion of the phosphoinositide 3-kinase p110γ gene attenuates murine atherosclerosis

  2007cited by this paper
• CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

  2006cited by this paper
• Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies

  2006cited by this paper
• Genomic and expression profiling identifies the B‐cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma

  2006cited by this paper
• Mechanisms of B-cell lymphoma pathogenesis

  2005cited by this paper
• The initiation of antigen-induced B cell antigen receptor signaling viewed in living cells by fluorescence resonance energy transfer

  2005cited by this paper
• Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity.

  2005cited by this paper
• Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer.

  2004cited by this paper
• Survival of Resting Mature B Lymphocytes Depends on BCR Signaling via the Igα/β Heterodimer

  2004cited by this paper
• Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure.

  2003cited by this paper
• Syk is required for integrin signaling in neutrophils.

  2002cited by this paper
• CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

  2002cited by this paper
• Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.

  2002cited by this paper
• CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

  2002cited by this paper
• Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration.

  2000cited by this paper
• Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton′s Tyrosine Kinase (BTK), LFM-A13 [α-Cyano-β-Hydroxy-β-Methyl-N-(2,5-Dibromophenyl)Propenamide]*

  1999cited by this paper
• Fetal hemorrhage and platelet dysfunction in SLP-76-deficient mice.

  1999cited by this paper
• Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

  1999cited by this paper
• The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages

  1993cited by this paper
• The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases

  1993cited by this paper

• BTK Inhibitor Downregulates IL-17 Secretion and Enhances CD20mb Sensitivity to ABC Type Diffuse Large B-cell Lymphoma via CYLD/NF-kB Signaling Pathway

  2025cites this paper
• Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112)

  2022cites this paper
• Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma

  2021cites this paper
• Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis.

  2021cites this paper
• Novel agents for the treatment of lymphomas during pregnancy: A comprehensive literature review.

  2021cites this paper
• A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.

  2020cites this paper
• Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.

  2020cites this paper
• Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients

  2020cites this paper
• HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development.

  2020cites this paper
• SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia

  2020cites this paper
• University of Birmingham A phase 2 randomised, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndrome

  2020cites this paper
• New responsibilities for aged kinases in B‐lymphomas

  2019cites this paper
• Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.

  2019cites this paper
• Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton’s tyrosine kinase inhibitors

  2019cites this paper
• The B‐cell receptor in control of tumor B‐cell fitness: Biology and clinical relevance

  2019cites this paper
• Lymph node fine‐needle cytology in the era of personalised medicine. Is there a role?

  2019cites this paper
• Investigation of MI-2 analogues as MALT1 inhibitors to treat of diffuse large B-Cell lymphoma through combined molecular dynamics simulation, molecular docking and QSAR techniques and design of new inhibitors

  2019cites this paper